Description of the main functions and effects of mirikizumab

As an IL-23-targeted antibody drug, Milikizumab's main efficacy focuses on improving the symptoms of moderate to severe ulcerative colitis, promoting intestinal mucosal healing, and reducing the risk of recurrence. In research, it has gradually shown potential therapeutic value for Crohn's disease (CD). With the global change in the concept of managing the course of inflammatory bowel disease, the medical community no longer only pursues symptom relief, but pays more attention to comprehensive goals such as intestinal mucosal repair, continuous control of inflammatory signals, and long-term stabilization of the course of the disease. Militizumab is a precision targeted therapeutic drug developed based on this background.

Its main effect is firstly reflected in improving intestinal inflammation. Many patients' symptoms originate from persistent inflammation of the mucosal layer, including abdominal pain, diarrhea, bloody stools, bloating, etc. WhenIL-23 signaling is overactive, intestinal immune cells continuously release inflammatory factors, preventing the mucosa from repairing normally, forming a cycle of continuous deterioration. Militizumab significantly reduces inflammatory activity by inhibiting the IL-23 pathway, giving the intestinal wall a chance to restore its normal structure. This is also the key reason why patients often experience "gradual relief of symptoms" after taking medication.

The second important role is to promote mucosal healing. In recent years, intestinal mucosal healing has been regarded as an important goal in the treatment of inflammatory bowel disease. Mucosal healing means that the condition is in a deeper stable state, which can reduce the risk of hospitalization, surgery, recurrence, etc. Milizumab can shift the intestinal environment from a state of excessive inflammation to a state of repair, gradually returning the intestinal mucosal surface structure to normal and improving the ability to absorb nutrients.

The third major benefit is a reduction in recurrence rates. Ulcerative colitis is characterized by periodic attacks, and many patients are troubled by frequent relapses that interrupt their life and work. Militizumab precisely regulates inflammation to make the maintenance period more stable, thereby extending the remission period and reducing symptom fluctuations. With long-term use, some patients' intestinal sensitivity to inflammatory stimuli decreases, making it easier to maintain a relatively healthy state.

Reference materials:https://omvoh.lilly.com/